The degree of neurocognitive impairment among patients with brain metastasis varies greatly. Besides the tumour mass effect, little has been known about how brain metastases impact brain function. Sanchez-Aguilera, Masmudi-Martín et al. now demonstrate that a molecular program, rather than brain tumour mass, is responsible for neurocognitive impairment and its variability.